August 1, 2025Open Access

Early Detection of Treatment Response to Mavacamten in Hypertrophic Obstructive Cardiomyopathy With Severe Mitral Regurgitation Using Magnetocardiography

PSPhillip SuwalskiHumboldt-Universität zu Berlin GSGamze SatilmisCharité - Universitätsmedizin Berlin MRMarkus ReinthalerHumboldt-Universität zu Berlin

Key Points

Mavacamten effectively reduces left ventricular outflow tract gradients in hypertrophic cardiomyopathy patients, suggesting its therapeutic value.
Key evidence includes a notable LVOT gradient reduction after treatment with mavacamten, illustrating its effectiveness.
Assessment using magnetocardiography shows promise as an objective monitoring tool for treatment responses in heart conditions.
This research highlights the potential of mavacamten and MCG in managing hypertrophic obstruction and warrants further exploration.

Abstract

ABSTRACT Recent evidence highlights the efficacy of mavacamten in reducing left ventricular outflow tract (LVOT) gradients in patients with hypertrophic cardiomyopathy (HCM), which is illustrated in this case. Additionally, the potential of magnetocardiography (MCG) as a novel, objective diagnostic and monitoring tool for nonischemic cardiomyopathies is demonstrated.

AIに質問

Bookmark

View Full Paper